MX2012011938A - Compuesto para tratamiento de condicion o enfermedad respiratoria. - Google Patents

Compuesto para tratamiento de condicion o enfermedad respiratoria.

Info

Publication number
MX2012011938A
MX2012011938A MX2012011938A MX2012011938A MX2012011938A MX 2012011938 A MX2012011938 A MX 2012011938A MX 2012011938 A MX2012011938 A MX 2012011938A MX 2012011938 A MX2012011938 A MX 2012011938A MX 2012011938 A MX2012011938 A MX 2012011938A
Authority
MX
Mexico
Prior art keywords
treatment
disease
compound
respiratory condition
exacerbations
Prior art date
Application number
MX2012011938A
Other languages
English (en)
Inventor
John Nicholas Lambert
Jane Ryan
Janet Marie Wilson
Original Assignee
Biota Scient Management
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2010901601A external-priority patent/AU2010901601A0/en
Application filed by Biota Scient Management filed Critical Biota Scient Management
Publication of MX2012011938A publication Critical patent/MX2012011938A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiera al tratamiento, alivio, prevención o reducción de síntomas o exacerbaciones de asma o enfermedad pulmonar obstructiva crónica, de la cual la función reducida del pulmón es típicamente sintomática.
MX2012011938A 2010-04-15 2011-04-14 Compuesto para tratamiento de condicion o enfermedad respiratoria. MX2012011938A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2010901601A AU2010901601A0 (en) 2010-04-15 Compound for the treatment of respiratory condition or disease
PCT/AU2011/000434 WO2011127538A1 (en) 2010-04-15 2011-04-14 Compound for treatment of respiratory condition or disease

Publications (1)

Publication Number Publication Date
MX2012011938A true MX2012011938A (es) 2013-01-28

Family

ID=44788654

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012011938A MX2012011938A (es) 2010-04-15 2011-04-14 Compuesto para tratamiento de condicion o enfermedad respiratoria.

Country Status (16)

Country Link
US (1) US20110257192A1 (es)
EP (1) EP2558097B1 (es)
JP (1) JP6148618B2 (es)
KR (1) KR20130106267A (es)
CN (2) CN105560245A (es)
AU (1) AU2011241478B2 (es)
BR (1) BR112012026244A2 (es)
CA (1) CA2796207A1 (es)
EA (1) EA025224B1 (es)
ES (1) ES2647223T3 (es)
IL (1) IL222244A0 (es)
MX (1) MX2012011938A (es)
NZ (1) NZ603040A (es)
SG (2) SG10201502391WA (es)
WO (1) WO2011127538A1 (es)
ZA (1) ZA201207696B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201508394UA (en) * 2013-04-12 2015-11-27 Obschestvo S Ogranichennoi Otvetstvennostiyu Pharmentpr Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
WO2015196113A2 (en) * 2014-06-20 2015-12-23 Biota Pharmaceuticals, Inc. Anhydrous crystalline free base form of-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzisoxazole

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR213700A0 (en) * 2000-12-18 2001-01-25 Biota Scientific Management Pty Ltd Antiviral agents
US20060167109A1 (en) * 2002-02-14 2006-07-27 Pevear Daniel C Methods of reducing rhinovirus contagion and related compositions
EP1596859B1 (en) * 2003-02-21 2008-07-02 Apodemus AB Treatment of diseases caused by ljungan virus by using pleconaril
US9308199B2 (en) * 2004-04-29 2016-04-12 Honeywell International Inc. Medicament formulations
US20060069124A1 (en) * 2004-09-07 2006-03-30 Rao P S Use of MDL-100,907 for treatment of allergic and eosinophil mediated diseases
AR057623A1 (es) * 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd Materiales y metodos para el tratamiento de las infecciones virales
CA2725618C (en) * 2008-05-27 2016-04-12 Biota Scientific Management Pty Ltd Antiviral salts
TW201016215A (en) * 2008-07-17 2010-05-01 Schering Corp Compositions and uses of antiviral active pharmaceutical agents

Also Published As

Publication number Publication date
AU2011241478A1 (en) 2012-11-01
EA201201416A1 (ru) 2013-03-29
EP2558097B1 (en) 2017-10-25
CA2796207A1 (en) 2011-10-20
SG184430A1 (en) 2012-11-29
US20110257192A1 (en) 2011-10-20
WO2011127538A1 (en) 2011-10-20
EA025224B1 (ru) 2016-12-30
KR20130106267A (ko) 2013-09-27
ES2647223T3 (es) 2017-12-20
CN105560245A (zh) 2016-05-11
EP2558097A1 (en) 2013-02-20
JP6148618B2 (ja) 2017-06-14
CN102844032A (zh) 2012-12-26
ZA201207696B (en) 2014-03-26
EP2558097A4 (en) 2013-09-11
NZ603040A (en) 2015-03-27
JP2013523844A (ja) 2013-06-17
AU2011241478B2 (en) 2016-12-01
SG10201502391WA (en) 2015-05-28
BR112012026244A2 (pt) 2016-07-12
IL222244A0 (en) 2012-12-31

Similar Documents

Publication Publication Date Title
WO2012110770A3 (en) Combination of glycopyrrolate and a beta2 -agonist
EA201190108A1 (ru) Фармацевтическая композиция для ингаляции
WO2015018840A3 (en) Novel means to decrease the negative effects of smoking
PH12015501108B1 (en) Treatment of pulmonary disease
TW200708513A (en) Novel crystalline forms of tiotropium bromide
TN2012000446A1 (en) Pyridine and pyrazine derivative for the treatment of cf
ZA201303960B (en) Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases
CA2897464C (en) Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide
EA201200876A1 (ru) Новые антагонисты рецептора ccr2 и их применение
GEP20186885B (en) Novel compounds
GB2468073A (en) Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
WO2005086915A3 (en) Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
MX2017009091A (es) Complejos de metal y desferroxiamina para el tratamiento de trastornos relacionados con la inmunidad.
EP3132799A4 (en) Pharmaceutical composition comprising pistacia weinmannifolia extract, fraction of same or compound separated from same for preventing or treating chronic obstructive pulmonary disease (copd)
MX351189B (es) Inhibidor de alfa1-proteinasa para demorar el comienzo o progresión de exacerbaciones pulmonares.
WO2009019598A3 (en) Inhalation therapy for respiratory disorders
EP2585067A4 (en) COMPOUND FOR THE TREATMENT OF ENTEROVIRUS
MX2019013468A (es) Metodos para tratar la enfermedad pulmonar obstructiva cronica usando benralizumab.
MX2012011938A (es) Compuesto para tratamiento de condicion o enfermedad respiratoria.
MX2012002091A (es) Uso de antibioticos en aerosol para el tratamiento de la enfermedad pulmonar obstructiva cronica.
TR201905319T4 (tr) Nevralji, ağrı, KOAH (Kronik, Obstruktif Akciğer Hastalığı) ve astım tedavisinde TRPM8-inhibitörleri olarak yararlı 2-aril-4-hidroksi-1,3-tiyazol türevleri.
UA115989C2 (uk) Фармацевтична композиція для інгалятора сухого порошку, що містить антагоністи мускаринових рецепторів тривалої дії
MX2016001539A (es) Particulas inhalables que comprenden tiotropio e indacaterol.
MX2010008685A (es) Farmacoforos duales-antagonistas muscarinicos de pde4.
BR112015004810A2 (pt) preparações de tiotrópio

Legal Events

Date Code Title Description
FC Refusal